Fulgent Genetics, Inc. Provides Earning Guidance for First Quarter of 2023 and Full Year 2023
February 01, 2023 at 02:35 am IST
Share
Fulgent Genetics, Inc. provided earning guidance for first quarter of 2023 and full year 2023. For first quarter of 2023, the company expects total Revenue of approximately $56.0 million.
For full year 2023, the company expects total revenue of approximately $240.0 million and GAAP loss of approximately $2.50 per share.
Fulgent Genetics, Inc. is a technology-based genetic company with a laboratory services business and a therapeutic development business. The Companyâs laboratory services business includes technical laboratory services and professional interpretation of laboratory results by licensed physicians. Its therapeutic development business is focused on developing drug candidates for treating a range of cancers using a nanoencapsulation and targeted therapy platform designed to improve the therapeutic window and pharmacokinetic profile (PK) profile of new and existing cancer drugs. Its technology platform for its laboratory services business includes gene probes, data suppression and comparison algorithms, learning software, and laboratory information management systems. The platform provides a test menu, the ability to rapidly develop and launch new tests and customizable test offerings. The Company also offers next-generation sequencing (NGS) services.
FULGENT GENETICS, INC. 
